| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/23/2002 | US6376473 Polynucleotide vaccine formula in particular against bovine respiratory pathology |
| 04/23/2002 | US6376459 Specific for gp39 on t cells was able to inhibit helper t-cell mediated b-cell activation by binding to a novel 39 kd protein receptor on helper t-cell membranes |
| 04/23/2002 | US6376246 Oligonucleotide mediated nucleic acid recombination |
| 04/23/2002 | US6376243 Capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding a mammalian 5-ht4b receptor. |
| 04/23/2002 | US6376228 Heterophil-adapted poultry vaccine |
| 04/23/2002 | US6376206 Specific antibodies to troponin T, their production and use in a reagent for the determination of myocardial necrosis |
| 04/23/2002 | US6376196 Contacting sample with isolated immunodominant neospora antigen, thereby forming antigen/antibody complex and detecting presence of antibodies specifically immunoreactive with bovine neospora antigen |
| 04/23/2002 | US6375985 System and method for producing drug-loaded microparticles |
| 04/23/2002 | US6375975 Pharmaceutical compositions for buccal and pulmonary application |
| 04/23/2002 | US6375955 Peptides |
| 04/23/2002 | US6375954 Size-variable strain-specific protective antigen for potomac horse fever |
| 04/23/2002 | US6375953 Treatment of infectious diseases with HSP70-peptide complexes |
| 04/23/2002 | US6375952 Isolated herpes simplex virus polypeptide |
| 04/23/2002 | US6375951 Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry |
| 04/23/2002 | US6375950 Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists |
| 04/23/2002 | US6375945 Qs-21 and qs-17, 3-o-deacylated monophosphoryl lipid a and interleukin 12, where qs-21 and qs-17 are derived from the bark of the south american tree quillaja saponaria molina |
| 04/23/2002 | US6375944 Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
| 04/19/2002 | WO2003040165A2 Hla class i and ii binding peptides and their uses |
| 04/19/2002 | CA2425648A1 Hla class i and ii binding peptides and their uses |
| 04/18/2002 | WO2002031198A2 Cancer-linked genes as targets for chemotherapy |
| 04/18/2002 | WO2002031181A2 Flea synaptic vesicle nucleic acid molecules, proteins and uses thereof |
| 04/18/2002 | WO2002031180A2 Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 04/18/2002 | WO2002031156A2 Bvh-a2 and bvh-a3 antigens of group b streptococcus |
| 04/18/2002 | WO2002031151A2 Lipocalins |
| 04/18/2002 | WO2002031140A1 Cells producing antibody compositions |
| 04/18/2002 | WO2002031128A1 Methods of agonizing and antagonizing fabk |
| 04/18/2002 | WO2002031117A2 Clasp-2 transmembrane proteins |
| 04/18/2002 | WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | WO2002031110A2 Hematopoietic stem cell gene therapy |
| 04/18/2002 | WO2002031025A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 04/18/2002 | WO2002030987A1 Antihuman heme oxygenase-1 monoclonal antibody |
| 04/18/2002 | WO2002030986A2 HUMANIZED ANTI-LT-β-R ANTIBODIES |
| 04/18/2002 | WO2002030984A1 Human anti-epidermal growth factor receptor single-chain antibodies |
| 04/18/2002 | WO2002030980A2 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/18/2002 | WO2002030979A2 Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same |
| 04/18/2002 | WO2002030970A2 Human histone deacetylase gene |
| 04/18/2002 | WO2002030968A1 Novel mite allergens and uses therefor |
| 04/18/2002 | WO2002030967A2 Novel compounds |
| 04/18/2002 | WO2002030964A2 Comparative ligand mapping from mhc positive cells |
| 04/18/2002 | WO2002030960A2 Polypeptide from haemophilus influenza |
| 04/18/2002 | WO2002030468A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | WO2002030463A2 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | WO2002030462A2 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | WO2002030461A2 Methods for treating disorders of the female reproductive system |
| 04/18/2002 | WO2002030458A1 Yersinia adhesion protein as vaccine adjuvant |
| 04/18/2002 | WO2002030434A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 04/18/2002 | WO2002030351A2 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030320A2 Stimulation of thymus for vaccination development |
| 04/18/2002 | WO2002030257A2 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | WO2002014499A9 Claudin polypeptides |
| 04/18/2002 | WO2002011742A3 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 04/18/2002 | WO2002009749A3 Respiratory syncytial virus vaccine |
| 04/18/2002 | WO2002004007A3 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof |
| 04/18/2002 | WO2002002642A3 Composition for pharmaceutical and cosmetic products |
| 04/18/2002 | WO2001098464A3 Continuous adherent melanocyte cell line |
| 04/18/2002 | WO2001093902A3 Immunostimulatory rna/dna hybrid molecules |
| 04/18/2002 | WO2001083744A3 Natrium-calcium exchanger protein |
| 04/18/2002 | WO2001083721A3 32132, a novel fucosyltransferase family member and uses therefor |
| 04/18/2002 | WO2001082958A3 Methods of producing membrane vesicles |
| 04/18/2002 | WO2001081579A8 Anti-idiotype inducing antibodies, comprising at least one epitope from angiogenin, for the inhibition of angiogenesis |
| 04/18/2002 | WO2001081574A3 Regulation of nf-at interacting protein nip 45 variant |
| 04/18/2002 | WO2001073037A3 R5 protein, a cell-surface protective antigen of group b streptococci |
| 04/18/2002 | WO2001070247A3 Salmonella vaccine materials and methods |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064856A3 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding |
| 04/18/2002 | WO2001064752A3 Antibody inhibiting the binding between gp120 and dc-sign and screening methods |
| 04/18/2002 | WO2001061007A9 Fibroblast growth factor-23 molecules and uses thereof |
| 04/18/2002 | WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001058483A3 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| 04/18/2002 | WO2001057073A3 Infectious cdna clone of hepatitis e virus (hev) genome, its production and uses |
| 04/18/2002 | WO2001056601A3 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 04/18/2002 | WO2001054718A3 Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions |
| 04/18/2002 | WO2001053457A3 Vaccines against neurodegenerative disorders |
| 04/18/2002 | WO2001051520A3 Nogo receptor-mediated blockade of axonal growth |
| 04/18/2002 | WO2001051080A3 Methods and compositions for obtaining disease protection for animals |
| 04/18/2002 | WO2001049712A3 Vaccine against isav (infectious salmon anaemia virus) |
| 04/18/2002 | WO2001046226A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 04/18/2002 | WO2001040271A3 Cancer associated antigens and uses therefor |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2000069454A9 Suppression of endogenous igfbp-2 to inhibit cancer |
| 04/18/2002 | WO2000067793A9 Death domain containing receptor 4 |
| 04/18/2002 | WO2000055192A3 Hemocyanin and nucleic acid sequence coding for the same |
| 04/18/2002 | US20020045737 Enterococcus faecalis polynucleotides and polypeptides |
| 04/18/2002 | US20020045594 Polynucleotide vaccine formulations |
| 04/18/2002 | US20020045587 Attenuated bacteria transformed with a promoter activated in cytosol of a host cell to produce a polypeptide lethal to the bacterium, and a host cell compatible promoter coding for therapeutic polypeptide such as an antigen; vaccination |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045571 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | US20020045241 T cells specific for kidney carcinoma |
| 04/18/2002 | US20020045231 Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies |
| 04/18/2002 | US20020045213 IL-17 receptor like molecules and uses thereof |
| 04/18/2002 | US20020045187 Methods and compositions for stimulating the immune system |
| 04/18/2002 | US20020045164 Reagents and methods useful for detecting diseases of the lung |
| 04/18/2002 | US20020044952 Attenuated live neospora vaccine |
| 04/18/2002 | US20020044951 Isolated and purified nonpeptide antigens from mycobacterium tuberculosis |
| 04/18/2002 | US20020044950 Recombinant toxin fragments |
| 04/18/2002 | US20020044949 Use in vaccination for preventing or treating Helicobacter infection |
| 04/18/2002 | US20020044948 Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| 04/18/2002 | US20020044946 12-25 kDa bacterial proteins and their 116-58 kDa polymers useful in anti-tumor vaccines |
| 04/18/2002 | US20020044945 Novel feline immunodeficiency virus nucleotide sequence |